Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Tel Aviv, Israel, filed Form 6-K for the month of February 2023. The filing primarily serves to incorporate by reference a press release issued on February 27, 2023, regarding a new supply agreement for its clinical trial on children with Autism Spectrum Disorder.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
The material change reported is the execution of an agreement for the supply of CBD-rich cannabis oil to support the Company's clinical trial focused on children with Autism Spectrum Disorder.
Guidance, Outlook, and Risks
Specific financial guidance or numerical outlook is not provided in this filing. The document incorporates "Forward-Looking Statements" from the attached press release (Exhibit 99.1) by reference, which typically contain risks and contingencies related to the clinical trial and supply chain, though the specific text of those statements is not included in the provided content.
Investor Verification Checklist
- Verify the terms and duration of the CBD-rich cannabis oil supply agreement.
- Review the full text of the press release (Exhibit 99.1) for details on the clinical trial timeline and regulatory status.
- Examine the incorporated "Forward-Looking Statements" for specific risks associated with the trial outcomes.
- Check subsequent filings for any updates on the trial progress or financial impact of the new agreement.